Alvotech initiates clinical studies for AVT04, a proposed biosimilar to Stelara® (ustekinumab)

Alvotech, in collaboration with the University of Iceland, has designed a training program for those who have recently graduated from the fields of biology, chemistry, biochemistry and pharmacology. The program is designed to train individuals to work in the biotech industry.

Create your own future - Is your future in biosimilars?

Alvotech bondholders convert more than $100m at pre-money valuation of $2.7bn

Alvotech reaches primary completion date in its switching study for AVT02, a proposed interchangeable biosimilar to AbbVie's Humira®

Róbert Wessman, Chairman of Alvotech, presented at the Jefferies Global Healthcare Conference, that took place in virtual format on June 1-4, 2021.

Robert Wessman presented at the Jefferies Global Healthcare Conference

Alvotech employees donate to UNICEF Covid relief in India

Alvotech seeks to end AbbVie’s wrongful monopoly on Humira and bring affordable arthritis treatment to U.S.

Alvotech proud sponsor of Reykjavik’s football club KR

Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab).

Alvotech disputes AbbVie’s allegations of wrongdoing

Alvotech has successfully completed a second round of its US$ 100 million private placement, for US$ 35 million.

Alvotech completes second round of a US$ 100m private placement

Alvotech and sister company Alvogen donate 100 thousand US dollars to UNICEF in combat against COVID-19

Cipla Gulf and Alvotech today announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.

Cipla Gulf and Alvotech expand partnership for commercialization of biosimilars in Australia and New Zealand

The Equal pay certification follows a rigorous process requiring specific policies, processes and controls to be implemented.

Alvotech Iceland receives Equal Pay Certification

A ground-breaking ceremony for the extension of Alvotech's high-tech centre in Reykjavík took place today. Robert Wessman, Chairman of the Board, Dagur B. Eggertsson, Mayor of Reykjavik and Jon Atli Benediktsson, Rector of the University of Iceland, took the first shoveling together with key employees who have been involved in the project.

Ground-breaking for the extension of Alvotech's high-tech centre in Reykjavik

Fuji Pharma will exclusively commercialize the medicines in Japan – discussions between the parties continue over additional biosimilar candidates

Alvotech and Fuji Pharma extend biosimilar partnership in Japan

Alvotech hf. and Alvotech & CCHT Biopharmaceutical Co., Ltd., which is the China joint venture company of Alvotech hf. and Changchun High & New Technology Industries (Group) Inc., have partnered with Yangtze River Pharmaceutical Group, a leading Chinese pharmaceutical company, to form an exclusive strategic partnership for the commercialization of eight biosimilar medicines in China.

Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical agree on an exclusive biosimilar partnership in China

Alvotech announces that the U.S. FDA and EMA have accepted regulatory submissions for AVT02, a proposed biosimilar to Humira® (adalimumab)

Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited, have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets such as South Africa.

Alvotech and Cipla partner to ensure access to biosimilars in South Africa

Alvotech announced today that its parent company, Alvotech Holdings SA, has successfully completed a $65 million private placement round.

Company news